Advertisement


Ann S. LaCasce, MD, on Hodgkin Lymphoma: PET-Adapted Therapy for Bulky Disease

2021 ASCO Annual Meeting

Advertisement

Ann S. LaCasce, MD, of Dana-Farber Cancer Institute, discusses results from the CALGB 50801 Alliance study, which showed that a PET scan–adapted approach may reduce the need for radiation treatment and may improve progression-free outcomes in patients with stage I/II bulky classic Hodgkin lymphoma (Abstract 7507).



Related Videos

Lung Cancer
Immunotherapy

Heather A. Wakelee, MD, on NSCLC: Atezolizumab vs Best Supportive Care After Chemotherapy

Heather A. Wakelee, MD, of Stanford University Medical Center, discusses the primary disease-free survival results of IMpower010, a phase III study that compared adjuvant atezolizumab vs best supportive care after adjuvant chemotherapy in patients with early-stage resected non–small cell lung cancer (Abstract 8500).

Colorectal Cancer
Immunotherapy

Thierry André, MD, on Pembrolizumab vs Chemotherapy in MSI-High Colorectal Cancer

Thierry André, MD, of Hôpital Saint-Antoine, discusses final overall survival data for the phase III KEYNOTE-177 study, which confirmed pembrolizumab as a new standard of care for first-line treatment of patients with microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer (Abstract 3500).

Lung Cancer
Immunotherapy

Martin Reck, MD, PhD, on NSCLC: Nivolumab, Ipilimumab, and Chemotherapy for Advanced Disease

Martin Reck, MD, PhD, of LungenClinic, discusses a 2-year update of the CheckMate 9LA study, which sought to determine whether nivolumab plus ipilimumab combined with two cycles of chemotherapy is more effective than four cycles of chemotherapy alone as a first-line treatment for patients with stage IV non–small cell lung cancer (Abstract 9000).

Prostate Cancer

Neeraj Agarwal, MD, on Prostate Cancer: Androgen-Deprivation Therapy With Orteronel or Bicalutamide

Neeraj Agarwal, MD, of Huntsman Cancer Institute at the University of Utah, discusses phase III data from the SWOG S1216 trial, which evaluated the clinical benefit of using androgen-deprivation therapy with either orteronel (or TAK-700, a CYP17 inhibitor) or bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (Abstract 5001).

Kidney Cancer
Immunotherapy

Brian I. Rini, MD, on RCC: Pembrolizumab Plus Axitinib vs Sunitinib as First-Line Therapy

Brian I. Rini, MD, of Vanderbilt University, discusses findings from KEYNOTE-426, the longest follow-up of a checkpoint inhibitor (pembrolizumab) combined with a VEGF/VEGFR inhibitor (axitinib) for first-line clear cell renal cell carcinoma. The trial results continue to support this combination as a standard of care for patients with previously untreated disease (Abstract 4500).

Advertisement

Advertisement




Advertisement